Cannabis : Neuropsychiatry and Its Effects on Brain and Behavior

Over the years, there has been increasing interest into the public health impact of cannabis use, especially by young adults. This follows the evidence of a growing prevalence of regular cannabis use worldwide, with approximately 200 million users. Recreational cannabis use, especially a frequent us...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (204 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545146504498
ctrlnum (CKB)5400000000040759
(oapen)https://directory.doabooks.org/handle/20.500.12854/68363
(EXLCZ)995400000000040759
collection bib_alma
record_format marc
spelling Colizzi, Marco edt
Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
Cannabis
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
1 electronic resource (204 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Over the years, there has been increasing interest into the public health impact of cannabis use, especially by young adults. This follows the evidence of a growing prevalence of regular cannabis use worldwide, with approximately 200 million users. Recreational cannabis use, especially a frequent use of products with high levels of its main psychoactive ingredient delta-9-tetrahydrocannabinol (Δ 9-THC), can cause dependence and have transient and long-lasting detrimental mental health effects, also negatively impacting cognitive processing and brain function and metabolism. In regular users, the development of tolerance to some of the effects of cannabis, especially the pleasurable ones, may lead to progressively heavier use in order to obtain the same effects in terms of their intensity, with higher health risks. However, the Cannabis Sativa plant contains different chemicals with different potential effects. In this regard, cannabidiol has gained interest because of its potential therapeutic properties, in line with evidence that CBD and Δ9-THC may exhibit opposite effects at the cannabinoid receptor type 1 (CB1), Δ9-THC being a partial agonist and CBD an antagonist/inverse agonist. Different cannabinoids may modulate human brain function and behavior in different ways, with different risk–benefit profiles.
English
Medicine bicssc
Neurosciences bicssc
delta-9-tetrahydrocannabinol
placebo
cannabis-associated psychosis
schizophrenia
BDNF
CB1
CB2
episodic memory
exercise
African American
black
older adult
marijuana use
cannabis use disorder
cue reactivity
craving
inhibitory control
frontal alpha asymmetry
EEG
cannabinoids
cannabis use
psychotic disorder
genetics
age of onset
clinical high risk
cannabis
memory
functional magnetic resonance imaging
THC
systematic review
gyrification
surface area
cortical surface structure
aerobic fitness
gender
endocannabinoid system
executive functions
problematic cannabis use
triple network
EEG functional connectivity
eLORETA
resting state
Delta-9-tetrahydrocannabinol
dronabinol
marijuana
randomized controlled trial
opioids
traumatic injury
alcohol
adolescents
fMRI
interoception
negative reinforcement
migraine: chronic pain
triptans
disability
3-03943-995-2
3-03943-996-0
Bhattacharyya, Sagnik edt
Colizzi, Marco oth
Bhattacharyya, Sagnik oth
language English
format eBook
author2 Bhattacharyya, Sagnik
Colizzi, Marco
Bhattacharyya, Sagnik
author_facet Bhattacharyya, Sagnik
Colizzi, Marco
Bhattacharyya, Sagnik
author2_variant m c mc
s b sb
author2_role HerausgeberIn
Sonstige
Sonstige
title Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
spellingShingle Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
title_sub Neuropsychiatry and Its Effects on Brain and Behavior
title_full Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
title_fullStr Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
title_full_unstemmed Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
title_auth Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
title_alt Cannabis
title_new Cannabis
title_sort cannabis neuropsychiatry and its effects on brain and behavior
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2021
physical 1 electronic resource (204 p.)
isbn 3-03943-995-2
3-03943-996-0
illustrated Not Illustrated
work_keys_str_mv AT colizzimarco cannabisneuropsychiatryanditseffectsonbrainandbehavior
AT bhattacharyyasagnik cannabisneuropsychiatryanditseffectsonbrainandbehavior
AT colizzimarco cannabis
AT bhattacharyyasagnik cannabis
status_str n
ids_txt_mv (CKB)5400000000040759
(oapen)https://directory.doabooks.org/handle/20.500.12854/68363
(EXLCZ)995400000000040759
carrierType_str_mv cr
is_hierarchy_title Cannabis Neuropsychiatry and Its Effects on Brain and Behavior
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1796651990396174336
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04152nam-a2201009z--4500</leader><controlfield tag="001">993545146504498</controlfield><controlfield tag="005">20231214133253.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/68363</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040759</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Colizzi, Marco</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cannabis</subfield><subfield code="b">Neuropsychiatry and Its Effects on Brain and Behavior</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Cannabis </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (204 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Over the years, there has been increasing interest into the public health impact of cannabis use, especially by young adults. This follows the evidence of a growing prevalence of regular cannabis use worldwide, with approximately 200 million users. Recreational cannabis use, especially a frequent use of products with high levels of its main psychoactive ingredient delta-9-tetrahydrocannabinol (Δ 9-THC), can cause dependence and have transient and long-lasting detrimental mental health effects, also negatively impacting cognitive processing and brain function and metabolism. In regular users, the development of tolerance to some of the effects of cannabis, especially the pleasurable ones, may lead to progressively heavier use in order to obtain the same effects in terms of their intensity, with higher health risks. However, the Cannabis Sativa plant contains different chemicals with different potential effects. In this regard, cannabidiol has gained interest because of its potential therapeutic properties, in line with evidence that CBD and Δ9-THC may exhibit opposite effects at the cannabinoid receptor type 1 (CB1), Δ9-THC being a partial agonist and CBD an antagonist/inverse agonist. Different cannabinoids may modulate human brain function and behavior in different ways, with different risk–benefit profiles.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurosciences</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">delta-9-tetrahydrocannabinol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">placebo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabis-associated psychosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">schizophrenia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BDNF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CB1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CB2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">episodic memory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exercise</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">African American</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">black</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">older adult</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">marijuana use</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabis use disorder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cue reactivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">craving</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inhibitory control</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frontal alpha asymmetry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EEG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabinoids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabis use</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psychotic disorder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">age of onset</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical high risk</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">memory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">functional magnetic resonance imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">THC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">systematic review</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gyrification</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">surface area</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cortical surface structure</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aerobic fitness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gender</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">endocannabinoid system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">executive functions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">problematic cannabis use</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triple network</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EEG functional connectivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">eLORETA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resting state</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Delta-9-tetrahydrocannabinol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dronabinol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">marijuana</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">randomized controlled trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">opioids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">traumatic injury</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alcohol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adolescents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fMRI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interoception</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">negative reinforcement</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">migraine: chronic pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">triptans</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disability</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-995-2</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-996-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhattacharyya, Sagnik</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Colizzi, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhattacharyya, Sagnik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:48:47 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337916470004498&amp;Force_direct=true</subfield><subfield code="Z">5337916470004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337916470004498</subfield></datafield></record></collection>